Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Heart Of A Pipeline: Can Novartis Keep The Cardio Portfolio Beating?

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The challenge of a generation shift in cardiovascular drugs is not new for Novartis, but the upcoming phase-out of Diovan through 2012 looks more difficult. As the firm prepares to lose Diovan exclusivity, its pipeline reflects an attempt to reprise the time-honored big pharma strategy that carried it through the loss of Lotrel in 2007: mix major efforts to develop novel, first-in-class agents with a push to accelerate its already marketed brands

You may also be interested in...



Efficacy Supplement Numbers On The Rise As Industry Braces For Patent Cliff

Drug makers are squeezing more new and expanded indications out of approved drugs to compensate for patent expiries and the lagging pace of new drug approvals, according to an analysis from the Tufts Center for the Study of Drug Development.

Efficacy Supplement Numbers On The Rise As Industry Braces For Patent Cliff

Drug makers are squeezing more new and expanded indications out of approved drugs to compensate for patent expiries and the lagging pace of new drug approvals, according to an analysis from the Tufts Center for the Study of Drug Development.

No Sales Model Left Behind: Novartis Joins Firms In Changing Market Focus

Novartis is joining the horde of pharmaceutical companies that are revamping their sales and marketing organizations in response to a U.S. market that is rapidly changing, at varying paces in different regions

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS004018

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel